publication date: Dec. 15, 2017

Five health systems join Strata Oncology network to sequence and match patients to targeted therapy trials

By Matthew Bin Han Ong

Five health care systems have joined a precision oncology network that sequences patients’ tumors at no cost and matches patients to clinical trials.

The network is sponsored by Strata Oncology, a precision medicine company based in Ann Arbor, MI. By partnering with hospitals and cancer centers via its Strata Precision Oncology Network, the company stratifies patient populations by disease and mutation and matches patients to pharma-sponsored trials to accelerate accrual.

The five health care systems that joined the network Dec. 13 are: University of Wisconsin Carbone Cancer Center, Christiana Care’s Helen F. Graham Cancer Centhatter & Research Institute, Kaiser Permanente-Northern California, Kettering Health Network, and Ochsner Health System.

The network’s existing members are: University of North Carolina Lineberger Comprehensive Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, and Metro Minnesota Community Oncology Research Consortium.

Strata was founded in 2016 by its CEO Dan Rhodes, a pathologist at the University of Michigan, and Keith Flaherty, an oncologist at Massachusetts General Hospital.

“Our business model is to create value by dramatically expanding patient access to tumor sequencing to accelerate the approval of breakthrough precision medicines,” Rhodes said to The Cancer Letter.

Continue reading Five health systems join Strata Oncology network to sequence and match patients to targeted therapy trials

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.